Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BARDA Backs Arcturus’ Influenza Vaccine Program

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) received an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority…
byVandana Singh
September 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) received an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA). 
  • The award provides three years to support preclinical, manufacturing, and nonclinical safety studies, along with development and regulatory support for Arcturus’ self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 studies.
  • Also see: Arcturus’ COVID-19 Booster Shows Durability Against Omicron Variants.
  • The company says its self-amplifying mRNA vaccine has been administered to over 10,000 individuals globally, demonstrating favorable safety, strong immunogenicity, and protection against SARS-COV-2 infection.
  • Price Action: ARCT shares are down 2.68% at $13.66 on the last check Thursday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst

By Vandana Singh
February 13, 3:05 PM
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800 million.

CBAY